Market data shows that the approval of oral GLP-1 weight-loss pills has led to a sharp rise in app usage, downloads and data tracking throughout the health-tech industry. However, people in the industry say that research on who can safely take these drugs has not kept up with how fast demand is growing.
The Numbers Behind The Boom
The wave traces back to two regulatory milestones. Novo Nordisk‘s (NYSE:NVO) oral Wegovy pill won approval in late 2025 and became broadly available by January 2026. Eli Lilly (NYSE:LLY) followed in April 2026 with Foundayo, known chemically as orforglipron, approved through the Food and Drug Administration‘s fast-tracked National Priority Voucher program.
In the months since, the app market has responded in kind. AppMagic, a mobile app intelligence firm, now owned by Sensor Tower, has tracked at least 568 new apps featuring “GLP-1” in their titles since January 2026. Most function as companions for GLP-1 users, handling medication scheduling, calorie tracking and side-effect monitoring.
The data also shows a pattern that AppMagic said it cannot fully explain. Downloads and revenue for GLP-1 tracker apps consistently rise on weekends, and this trend shows up even in downloads that are not driven by paid advertising. The firm said this “could be influenced by factors such as UA [User Acquisition] activity and changes in users’ routines around the weekend, including planning meals and activities for the week ahead.”
A Crowded Field Chases Scale
Among the apps benefiting from this trend is Glapp, one of the top five apps by revenue among those with “GLP-1” explicitly in their title, according to AppMagic. Its CEO and co-founder, Artem Kosarev, said in a statement to Benzinga that “GLP-1 demand is definitely the macro-trend,” adding that the app reached 100,000 users through organic growth alone in its first year.
Speaking about the broader market, Kosarev said there are more than 200 GLP-1 apps in the App Store. He noted that many were developed by individuals who may not have strong privacy or data security standards. Others were created by teams that have not personally experienced the therapy. He added that “only a handful of apps are treating this with the required clinical rigor: building on research, working with physicians, and prioritizing data privacy.” He predicted, “a few clear leaders will emerge over the next year because the bar for doing this properly is much higher than it looks from the outside.”
The Bigger Shift Behind The Boom
The app boom isn’t happening in isolation. It is part of a much broader shift in how the health care industry is responding to growing demand for GLP-1 drugs. In an interview with Benzinga, Gerald Commissiong, interim co-CEO of DataMEDS AI Inc. (NASDAQ:MEDS), a Florida-based health IT company with its own GLP-1-related business, offered a perspective from outside the app industry on what is driving this change.
According to Commissiong, one factor is a regulatory change that expanded the approved uses of GLP-1 drugs to include weight loss, rather than limiting them to diabetes treatment.
“Now weight loss being characterized as a disease… changes the way in which people engage with healthcare, because obesity was more of a lifestyle issue, and now being categorized as a disease means that you can develop drugs for it,” Commissiong said.
When asked whether the current surge is being driven specifically by the pills or by GLP-1 demand more broadly, Commissiong said the demand is happening across the board. He said every era has had its own weight loss trend or weight loss expert, and right now that role happens to be filled by pharmaceutical companies, who are, in his view, far more effective.
When asked about consumer GLP-1 tracking apps like Glapp, MeAgain and Pep, which have quickly built up users, Commissiong said these apps appear to be an effort to bring objective data and coaching into the process.
Responding to whether DataMEDS has its own consumer-facing app for tracking or managing GLP-1 use, Commissiong said that it does. “We believe the app that we have built will more effectively [do that],” he said, without naming the app.
DataMEDS has already announced its app, called Health Lives Here. The app is designed first for patients coping with muscle loss linked to GLP-1 drugs and for those dealing with long COVID. The company said it plans to use the app’s tools for patient engagement to bring electronic health records onto its own blockchain system. Through this system, patients could earn a share of revenue from data transactions. The plan is also meant to cut down on data-sharing problems for health care providers. In addition, the company wants to offer clinical trials tailored to patients, covering both prescription drugs and its own nutraceutical products.
A Warning Amid The Growth
Commissiong’s most striking comments came when asked about the science underlying the category. “There have been no trials on GLP-1 in patients who are not obese,” he said. “We don’t know what the risks are.”
He explained the regulatory logic behind that gap, “When you approve a weight loss drug, you approve it for people who are overweight… because the benefit outweighs the risk.” That calculation, he said, doesn’t necessarily extend to a growing pool of non-obese users now seeking access to the drugs.
On specific risks, Commissiong pointed to muscle loss as a widely acknowledged side effect and said that postmenopausal women may be particularly vulnerable. He explained that taking drugs that accelerate muscle loss can also accelerate many other health problems, making this very dangerous. He also mentioned gastroparesis, where the gut stops moving, and vision loss as other significant side effects that have emerged.
Image via Shutterstock/ KK Stock
Recent Comments